Eli Lilly (LLY)

1,005.75
-2.64 (-0.26%)
NYSE · Last Trade: Mar 10th, 2:16 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,008.39
Open1,006.00
Bid1,005.29
Ask1,006.01
Day's Range994.00 - 1,012.00
52 Week Range623.78 - 1,133.95
Volume736,342
Market Cap962.08B
PE Ratio (TTM)43.82
EPS (TTM)22.9
Dividend & Yield6.920 (0.69%)
1 Month Average Volume3,090,429

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Novo Nordisk Sentiment Shifts as REDEFINE 4 Trial Results Trigger 16% Stock Plunge
The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3 trial. For years, the Danish pharmaceutical giant was the undisputed leader of the GLP-1 revolution, but the
Via MarketMinute · March 10, 2026
Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Lossstocktwits.com
As per the CEO, the company will have four late-stage trials by the end of 2026.
Via Stocktwits · March 10, 2026
2 Healthcare Stocks That Are Too Cheap to Ignorefool.com
These companies' shares have fallen too far, offering investors an attractive opportunity.
Via The Motley Fool · March 10, 2026
Eli Lilly & Co (NYSE:LLY) Presents a Compelling Mix of Strong Growth and Bullish Chart Formationchartmill.com
Via Chartmill · March 10, 2026
Eli Lilly & Co (NYSE:LLY) Emerges as a Prime GARP Investment Candidatechartmill.com
Via Chartmill · March 7, 2026
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering "hangover" period in 2023 and 2024, the pharmaceutical giant is currently in the middle of a high-stakes transformation. The company is attempting to [...]
Via Finterra · March 10, 2026
From Red to Green: How Trump's Iran Endgame Sparked a Wall Street Comebackchartmill.com
Via Chartmill · March 10, 2026
Should You Buy Eli Lilly Stock Now or Wait for More of a Pullback?fool.com
Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.
Via The Motley Fool · March 9, 2026
Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stockfool.com
The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.
Via The Motley Fool · March 9, 2026
The 2026 M&A Resurgence: Private Equity Confidence Hits Record Highs
The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,
Via MarketMinute · March 9, 2026
2 Top AI Healthcare Stocks to Buy and Holdfool.com
AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.
Via The Motley Fool · March 9, 2026
The Pivot to Legitimacy: Hims & Hers Health (HIMS) Faces a New Era of Personalized Medicine
Date: March 9, 2026Sector: Healthcare TechnologyCompany: Hims & Hers Health, Inc. (NYSE: HIMS) Introduction As of March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at perhaps the most critical juncture in its nine-year history. Once viewed as a disruptive "millennial-focused" telehealth startup specializing in hair loss and sexual health, the company [...]
Via Finterra · March 9, 2026
Contrarian Take: Vanguard's 3 Worst-Performing Equity ETFs in 2026 Are All Buys in Marchfool.com
In a matter of months, last year's winners have shifted to losers, creating compelling buying opportunities for long-term investors.
Via The Motley Fool · March 9, 2026
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoidfool.com
Eli Lilly may be the GLP-1 leader, but its valuation is stretched.
Via The Motley Fool · March 8, 2026
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000fool.com
This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.
Via The Motley Fool · March 8, 2026
2 Underrated Weight Loss Stocks to Buy Nowfool.com
These companies have a lot more to offer than their prospects in the weight loss market.
Via The Motley Fool · March 8, 2026
Where Will Eli Lilly Stock Be in 10 Years?fool.com
Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.
Via The Motley Fool · March 7, 2026
Can This Next-Gen Obesity Drug Save Novo Nordisk?fool.com
Things can't get that much worse for the drugmaker.
Via The Motley Fool · March 7, 2026
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?fool.com
Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.
Via The Motley Fool · March 6, 2026
Tariffs News & Market Chaosfool.com
President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.
Via The Motley Fool · March 6, 2026
Here's How Much $1000 Invested In Eli Lilly 5 Years Ago Would Be Worth Todaybenzinga.com
Via Benzinga · March 6, 2026
HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdownstocktwits.com
The stake reduction comes as Hims navigates regulatory scrutiny over weight-loss drugs, while expanding into other healthcare categories.
Via Stocktwits · March 6, 2026
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investorsfool.com
Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.
Via The Motley Fool · March 5, 2026
The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026
As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international equity markets are not just keeping pace with their American counterparts but are decisively outperforming them. While
Via MarketMinute · March 5, 2026
Renovations and Equipment Upgrades Fell 18% in February 2026; Other Capital Projects Remain Stable
JACKSONVILLE BEACH, Fla., March 5, 2026 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads released its February 2026 Planned Capital Project Spending Report for the Industrial Manufacturing sector. The firm tracks industrial capital investment activity across North America, including facility expansions, new plant construction, and significant equipment modernization projects.
Via Send2Press · March 5, 2026